$NXGL News

NEXGEL Announces 1-for-20 Reverse Stock Split Effectiveness

NEXGEL Announces 1-For-20 Reverse Stock Split, Effective Immediately

NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation Transcript

NEXGEL Announces Dial-In Details for Investor Update Call

NEXGEL Announces Date for Investor Update Call

Maxim Group Downgrades NexGel to Hold

NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE

NEXGEL Appoints Brian Kieser As Interim CEO; Co. Forms Special Committee For Strategic Review And Value Creation

NEXGEL Q2 Revenue Reaches $3.69 Million as BioNX Integration Faces Slower Ramp

NEXGEL Reports Second Quarter 2026 Financial Results

NexGel Q2 EPS $(0.40) Misses $(0.12) Estimate, Sales $3.686M Miss $4.315M Estimate

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

NEXGEL Announces Data From Randomized, 30-Patient, Single-Center IRB Clinical Study, Funded By Innovative Optics

Nexgel (NXGL) Q1 2026 Earnings Transcript

NexGel Q1 2026 Earnings Call Transcript

NexGel Q1 EPS $(0.11) Misses $(0.07) Estimate, Sales $2.650M Miss $3.909M Estimate

NEXGEL, Inc. Q1 2026 Earnings Call Summary

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NEXGEL To Report First Quarter 2026 Financial Results on May 15th